initiated with intravenous meropenem (3g/day), tigecycline (100 mg every 12 h) and clindamycin (600 mg/day). Filgastrim (48000 μg/day subcutaneous) was also administered.

A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19 Anubhav Kanwar 1,* , Alex Jordan 2, Scott

Neuroophthalmology of invasive fungal sinusitis: 14 consecutive patients and a review of the literatureOriginal Article Neuro-ophthalmology of invasive fungal sinusitis:

Mucormycosis: an emerging disease?REVIEW Mucormycosis: an emerging disease? E. Bouza, P. Munoz and J. Guinea Servicio de Microbiologa Clnica y Enfermedades Infecciosas, Hospital

Ivett Miranda1 Jorge Ocampo-Candiani1 Oliverio Welsh1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20176614 Abstract: Cutaneous mucormycosis is an emerging fungal infection

National Centre for Disease Control, Directorate General of Health Services, Government of India Mucormycosis (previously known as infection caused by a group of molds called

Mucormycosis_Management_COVID19Pain and redness around eyes and/or nose Fever Headache Coughing Shortness of breath Bloody vomits Altered mental status This can lead to serious

pISSN 2093-2340 · eISSN 2092-6448 Received: April 23, 2013 Revised: July 17, 2013 Accepted: July 18, 2013 Corresponding Author : Sang-Oh Lee, MD, PhD Department of

Mucormycosis in a patient with COVID-19 with uncontrolled diabetesMucormycosis in a patient with COVID-19 with uncontrolled diabetes Muhammad Shakir,1 Muhammad Hassaan